Joseph Scheeren, PharmD
Joseph Scheeren, PharmD, is President and Chief Executive Officer of Critical Path Institute, an Arizona based nonprofit (501(c)(3)). Scheeren leads the Institute in its mission to catalyze the development of new tools to advance medical product innovation and regulatory science. C-Path establishes and leads teams that share data, knowledge and expertise resulting in sound, consensus-based science. Scheeren assumed the role of President and CEO in April 2019. He previously served as Senior Advisor Research and Development for Bayer AG.
Scheeren has had a distinguished 36-year career in the pharmaceutical industry having held positions domestically and internationally in drug development and regulatory approval on three continents. He has in-depth knowledge and leadership experience with drug development and the regulatory process which is evidenced by a long list of first cycle approvals for new therapies he has been directly involved in.
Scheeren joined Bayer Pharmaceuticals as Senior Vice President, Head of Global Regulatory Affairs, in 2004, responsible for development in the US and in 2009 became Site Head US in Montville, NJ. In 2012, he assumed the position of Head of Global Development Asia in Beijing and in 2015, was appointed Head of Global Regulatory Affairs Pharma and Consumer Care of Bayer Healthcare, Basel, Switzerland. In January 2018, he was appointed Senior Advisor R&D, Bayer AG. Scheeren’s experience with global regulatory affairs will help C-Path expand its mission worldwide.
He has an established network of connections across the globe and holds many memberships and designations. He serves on the advisory boards at the Center for Innovation in Regulatory Science, the Center of Regulatory Excellence Singapore, the Research & Development-based Pharmaceutical Association in China, and the China Core Research and Development Committee. He is currently serving as Board chair of the Drug Information Association (DIA) and has served as Chairman of the DIA Regional Advisory Council for Europe, the Middle East and Africa; he is also a foreign member of the Academie Nationale de Pharmacie, France, a lecturer at Yale University and an adjunct Professor at Peking University.